Efficacy and Safety of Brodalumab, An Anti-Interleukin-17 Receptor A Monoclonal Antibody, in Japanese Patients with Palmoplantar Pustulosis: A 16 Week Results of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Brodalumab is a fully human IgG2 monoclonal antibody with selective binding of the IL-17 receptor.
• 126 patients randomized to brodalumab 210 mg Q2W or placebo for 16 weeks; all patients received brodalumab in the open-label extension.
• PPPASI total score change from baseline was significantly higher with brodalumab: 13.73 versus 8.45 with placebo.
• Similarly, by Week 16 16.0% versus 0.0% achieved PPPASI-90 response.
• 210 mg Q2W was effective and tolerable in Japanese PPP patients, and may provide a new treatment option.